CABALETTA BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
CABALETTA BIO, INC. (CABA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 3.70% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-08-13
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2026-03-31 was 3.70%, a 7.04% decline year-over-year.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2025-03-31 was 3.98%, a 5.29% increase year-over-year.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2024-03-31 was 3.78%, a 11.83% increase year-over-year.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2023-03-31 was 3.38%, a 129.93% increase year-over-year.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2025 was 3.72%, a 8.45% increase from fiscal 2024.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2024 was 3.43%, a 1.48% increase from fiscal 2023.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2023 was 3.38%, a 129.93% increase from fiscal 2022.
- CABALETTA BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.47%, a 133.33% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.70% 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | 3.70% 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | 3.72% 10-K · filed 2026-03-23 | |||
| 2025-09-30 | 3.94% 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 3.94% 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | 3.98% 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | 3.43% 10-K · filed 2026-03-23 | |||
| 2024-09-30 | 3.43% 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | 3.78% 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 3.78% 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | 3.38% 10-K · filed 2025-03-31 | |||
| 2023-09-30 | 3.38% 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | 3.38% 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 3.38% 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | 1.47% 10-K · filed 2024-03-21 | |||
| 2022-09-30 | 1.47% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 1.47% 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 1.47% 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 0.63% 10-K · filed 2023-03-16 | |||
| 2021-09-30 | 0.63% 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 0.63% 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | 0.63% 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 0.28% 10-K · filed 2022-03-17 | |||
| 2020-09-30 | 0.28% 10-Q · filed 2021-11-01 | |||
| 2020-06-30 | 0.42% 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 0.93% 10-Q · filed 2021-05-03 | |||
| 2019-12-31 | 1.39% 10-K · filed 2021-03-16 | |||
| 2019-09-30 | 1.39% 10-Q · filed 2020-11-10 | |||
| 2019-06-30 | 1.82% 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | 2.23% 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | 2.92% 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |